🇺🇸

US SEC Filing Intelligence

· daily

US SEC Trading Suspension Halt Orders — May 21, 2026

The two filings in this stream both involve US exchange listing compliance issues, highlighting a theme of regulatory and financial distress among smaller-cap companies. Picard Medical shows a stark contrast between strong operational improvement (85% YoY revenue growth, achieving a positive gross margin of 24%) and a deteriorating balance sheet (stockholders' deficit of $(1.4)M), leading to two NYSE American delisting notices. Hub Group's situation is a non-operational, administrative delay in filing its Q1 2026 10-Q, following a prior delay on its 2025 10-K, which has resulted in a Nasdaq non-compliance notice. The key portfolio-level trend is the divergence between operational performance and financial/regulatory health, with Picard's growth being overshadowed by solvency risks, while Hub Group's risk is purely procedural. The most critical development is Picard's June 7, 2026 deadline to submit a compliance plan, which will be a key catalyst for its stock. No insider trading activity was reported in either filing, removing a key sentiment gauge.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 21, 2026

The 50 filings reveal a bifurcated market with aggressive capital raising and strategic portfolio reshaping amid rising distress signals. A dominant theme is the wave of equity and debt offerings, with 12 companies raising capital through dilutive stock sales, convertible notes, or private placements, signaling acute cash needs. Concurrently, major portfolio optimization is underway, highlighted by the $69 billion AvalonBay/Equity Residential merger of equals and significant divestitures by Kontoor Brands (Lee® for up to $1B), Conduent (Public Transit for $164M), and Sun Communities (UK assets for ~$1.03B). Distress is concentrated among micro-cap biotechs and struggling tech firms, with 4 companies executing reverse stock splits to maintain exchange listings and 2 receiving delisting notices. Period-over-period data, though limited, shows mixed results: Hims & Hers grew revenue 44.8% YoY but missed guidance, while Picard Medical grew revenue 85% YoY but saw net losses widen. Insider activity is sparse, but the prevalence of related-party transactions and distressed financings suggests management is prioritizing survival over shareholder value. The overall sentiment is cautious, with a clear trend toward deleveraging, portfolio simplification, and reliance on capital markets for liquidity.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — May 21, 2026

The May 21, 2026 regulatory filings reveal a period of significant leadership upheaval across US equities, with 13 CEO/President departures or successions, 8 CFO changes, and 16 director shifts, concentrated in financials, technology, and healthcare. Period-over-period analysis from the enriched data shows a clear divergence: while several companies like Jet.AI and NRG Energy are aggressively pivoting toward AI infrastructure (with Jet.AI's cash position surging from $1.8M to $13.5M but revenue collapsing 51.6% YoY), traditional sectors face margin compression and shareholder dissent. Notably, 8 of 50 filings (16%) revealed advisory say-on-pay votes with >7% opposition, signaling growing governance concerns, and 5 companies saw director elections with >10% against votes. Insider activity was limited but material: the Radian Group CEO succession ($1M base + $14M total compensation package) and Sterling Infrastructure's CEO extension with a unique 'successor-onboarding' RSU vesting condition highlight a trend toward performance-based retention. Capital allocation signals are mixed—Aebi Schmidt and Valhi declared stable dividends, while Rithm Capital's 35M share reserve increase (69.24M total) amid 15% advisory vote opposition suggests potential dilution risk. The most critical development is Glimpse Group's near-total leadership vacuum (CEO, CFO, Chair all resigned), creating acute uncertainty, while Kohl's 5.2M share plan amendment passed despite 19.8M broker non-votes signals cautious but ongoing retail restructuring.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 21, 2026

The 50 filings from May 21, 2026, reveal a significant wave of leadership transitions across US public companies, with a notable concentration in the financial and energy sectors. A key theme is the high level of shareholder dissent on executive compensation and equity plan approvals, with several companies (BankUnited, MaxLinear, ANI Pharmaceuticals) seeing 7-15% opposition, signaling growing investor activism. The data shows a clear pattern of insider confidence, with several companies appointing new CFOs and CEOs, while others like Glimpse Group and Jet.AI face near-complete leadership turnover or severe financial distress. Capital allocation remains mixed, with dividend increases at Aebi Schmidt and American Tower contrasting with ongoing cash burn at Jet.AI and leadership departures at Omega Healthcare. The most critical development is the high materiality events at Glimpse Group (9/10) and Jet.AI (9/10), which present both significant risk and potential turnaround opportunities. Overall, the filings suggest a market in transition, with companies aggressively managing succession plans while facing heightened shareholder scrutiny on governance and pay practices.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — May 21, 2026

Today's digest covers 9 SEC filings, with 5 new entries and 4 for context, revealing a bifurcated M&A landscape. The most material developments are two transformative acquisitions: Nocopi Technologies' $2.65M purchase of Polymeric US, which more than triples its revenue base, and Ondas Holdings' acquisition of Omnisys, which adds over $100M in high-margin defense revenue. However, the SPAC market shows significant stress, with GSR V Acquisition Corp. reporting a going concern warning and an accumulated deficit of $7.3M despite a $230M IPO. Period-over-period comparisons are limited as most filings are for newly formed SPACs, but the operational companies (Nocopi, Ondas) show strong forward-looking revenue growth. Insider activity is notable at Nocopi, where a new director and an affiliate purchased shares in a private placement, signaling confidence. Capital allocation is mixed, with Nocopi using a mix of cash and stock (dilutive) while Ondas pursues a high-growth, high-margin acquisition. The overarching theme is a 'haves vs. have-nots' dynamic: companies with clear operational targets (Nocopi, Ondas) are executing, while cash-rich SPACs face existential risks.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 21, 2026

Overnight filings reveal a market bifurcated between aggressive corporate restructuring and operational headwinds. The most significant development is the transformative $1.03B UK asset sale by Sun Communities and the blockbuster AvalonBay-Equity Residential merger, signaling major consolidation in real estate. In earnings, Deere & Co. posted a 5% revenue increase but saw a 2% profit decline, with a sharp 39% drop in its core Production & Precision Agriculture segment, highlighting a mixed industrial outlook. Conversely, e.l.f. Beauty reported a strong 24.6% revenue surge, but net income collapsed 76.5% due to acquisition-related charges, a classic growth-at-a-cost story. A notable cluster of 14 Puerto Rico closed-end funds is pursuing a strategic shift to open-end structures, a potential liquidity catalyst for a previously illiquid market. Insider activity was sparse, but significant shareholder dissent was observed at Rocket Pharmaceuticals, where a director received only 68.2% support. Overall, the data points to a market where balance sheet strength and strategic clarity are rewarded, while companies facing operational decay (DHTI) or dilution risk (Snail, Inc.) are flashing clear warning signs.

27 high priority 23 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — May 20, 2026

This digest covers a single $62.7 million civilian contract awarded by the Department of State to SICRA ILE DE FRANCE for construction of a residential facility in Paris. The contract is entirely civilian, with no defense exposure, and represents a niche opportunity in overseas diplomatic infrastructure. The highest-conviction signal is neutral, reflecting the absence of a publicly traded parent and limited direct portfolio impact. Key risks include execution pressure from the firm-fixed-price structure and potential budget volatility for State Department foreign operations. Investors should monitor follow-on awards and cost performance disclosures for sector-wide margin implications.

1 total filings
· daily

Defense Manufacturing Contracts — May 20, 2026

The single contract in this period, a $569.5M firm-fixed-price delivery order from NASA to Northrop Grumman for the JPSS-2 spacecraft, represents a purely civilian space systems award with no defense exposure. The aggregate obligation is entirely non-defense, highlighting NASA's continued investment in critical polar satellite infrastructure for weather and climate monitoring. The highest-conviction signal is bullish for Northrop Grumman, given the 13-year performance period and high strategic importance, but the fixed-price structure introduces execution risk on a complex space vehicle program. Key watch items include progress on JPSS-2 delivery milestones and the potential exercise of $37.2M in options to increase total contract value.

1 total filings
· daily

DHS Homeland Security Contracts — May 20, 2026

This digest covers a single $98.8M civilian contract from the Department of Homeland Security (DHS) to Leidos, Inc., representing 100% of the period's total obligation. The contract is for low-energy non-intrusive inspection systems for Customs and Border Protection (CBP), a firm-fixed-price delivery order with options extending to 2033. The highest-conviction signal is neutral: the award signals stable border security technology spending and Leidos' execution capability, but the long duration, 22% subaward concentration, and fixed-price risk temper the bullish case. Key risk is DHS budget appropriations for border technology, which could affect option exercise or renewal beyond 2027.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — May 20, 2026

Over a single day, May 20, 2026, the Department of Health and Human Services (HHS) awarded two defense-related contracts totaling $134.8 million, both under BARDA for medical countermeasure R&D. The dominant theme is biodefense and antimicrobial resistance (AMR) preparedness, with Venatorx Pharmaceuticals receiving a $72.1M cost-plus-fixed-fee contract (potential $318.6M) for an AMR antibiotic, and SELUX Diagnostics receiving a $62.6M contract (potential $70.6M) for biotechnology R&D. The highest-conviction signal is Venatorx’s long-duration (through 2032) contract tied to a priority national security area, but both awards carry neutral signals due to cost-plus pricing limiting upside and SELUX’s contract ending May 2025, creating near-term revenue cliff risk. Key watch items include option exercises for Venatorx and SELUX’s ability to secure follow-on awards.

2 total filings
· daily

New Federal Contractors — May 20, 2026

This digest of 11 new federal contracts, totaling $1.87 billion, reveals a civilian-agency-dominated landscape (9 of 11 contracts) with NASA as the standout spender, accounting for $1.08 billion (58%) of total obligations. The highest-conviction signal is Northrop Grumman's $569.5 million firm-fixed-price delivery order for the JPSS-2 spacecraft, a long-duration (13-year) NASA/NOAA polar satellite program that reinforces its competitive moat in large space systems. Key risks include execution pressure on fixed-price contracts for complex space vehicles and the absence of defense-related awards from the DoD, which limits near-term defense sector exposure. Investors should watch NASA's budget trajectory for Earth science and space R&D, as well as option exercises on the RTX and Venatorx contracts.

11 total filings
· daily

Significant Contract Modifications ($10M+) — May 20, 2026

This digest of 11 government contracts, totaling $1.87 billion in obligations from a single day (May 20, 2026), reveals a pronounced civilian-agency tilt, with only 2 of 11 contracts defense-related. NASA dominates the period, accounting for $1.085 billion (58%) of total value, driven by a $569.5 million Northrop Grumman JPSS-2 spacecraft delivery order and a $445 million Caltech/JPL R&D award. The highest-conviction signal is the Northrop Grumman contract, a long-duration, fixed-price win that reinforces its competitive moat in large space systems but carries execution risk. A key watch item is the heavy concentration in NASA and HHS (combined $1.36 billion, 73% of total), which exposes investors to civilian budget risk, particularly under a potential Continuing Resolution (CR) scenario that could delay new obligations. No bearish signals were identified, but neutral signals on nine contracts highlight limited near-term margin catalysts and execution risks on fixed-price awards.

11 total filings
· daily

Contract Deobligations Alert — May 20, 2026

This digest of 11 contracts, totaling $1.87 billion in obligations, reveals a heavily civilian-skewed procurement landscape (9 of 11 contracts) led by NASA and HHS, with defense-related awards comprising only 2 contracts. The highest-conviction signal is Northrop Grumman's $569.5M firm-fixed-price NASA award for the JPSS-2 spacecraft, a long-duration, high-materiality win that reinforces its competitive moat in space systems. A key risk is the lack of any DOD contracts in the set, suggesting a potential pause or CR-related slowdown in defense procurement during this period, while civilian agency spending—particularly NASA space R&D and HHS health security—remains robust. Investors should watch for execution risk on Northrop Grumman's fixed-price space vehicle contract and monitor NASA budget allocations for Earth science programs that underpin RTX's $200M Landis instrument award.

11 total filings
· daily

Contract Option Exercises — May 20, 2026

This digest covers 11 contract option exercises totaling $1.87B, with only 2 defense-related awards (18%) and the remainder civilian, primarily NASA and HHS. The dominant theme is NASA's sustained investment in space R&D and Earth science, led by a $569.5M Northrop Grumman JPSS-2 spacecraft award—the highest-conviction bullish signal. The aggregate signal strength is moderate (5.2/10), reflecting a mix of large, stable NASA contracts and smaller civilian IT and health awards with limited direct equity exposure. Key risk: the heavy civilian tilt (9 of 11 contracts) exposes investors to potential budget scrutiny under a Continuing Resolution, while the absence of DOD contracts limits defense sector upside.

11 total filings
· daily

Federal Professional Services Contracts — May 20, 2026

This digest covers a single $151.7M civilian agency contract awarded to Magellan Federal (Centene subsidiary) by the Department of the Interior, with no defense exposure. The contract provides personal financial counselors on a time-and-materials basis, signaling stable but margin-capped recurring revenue. The highest-conviction signal is the neutral-to-bearish pricing structure (T&M) and high subaward pass-through ($45.9M), which limits margin expansion and competitive moat. Key risks include budget scrutiny for non-core civilian support functions and potential option year non-exercise.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — May 20, 2026

The two civilian Health and Human Services contracts awarded to Deloitte & Touche LLP and SOFTRAMS LLC total $138.1 million in obligations, with zero defense exposure. The dominant theme is sustained federal IT modernization, specifically at NIH’s National Cancer Institute and CMS, where demand for digital services and application development remains robust. The highest-conviction signal is Deloitte’s $69.7 million obligated contract, which provides near-term revenue visibility for the privately held firm, though its lack of public equity limits direct investment applicability. A key risk is SOFTRAMS LLC’s fixed-price execution burden, which could compress margins for this small HUBZone business if costs overrun. Overall, the digest signals stable civilian IT spending but offers limited actionable equity opportunities due to the private status of both recipients.

2 total filings
· daily

NASA & Space Contracts Intelligence — May 20, 2026

This digest covers $1.28B in NASA-only contracts awarded to three entities—Northrop Grumman, Caltech (JPL), and RTX Corp (Raytheon)—with zero defense-related obligations, underscoring a pure civilian space and science procurement theme. The highest-conviction signal is Northrop Grumman's $569.5M firm-fixed-price delivery order for the JPSS-2 spacecraft, a 13-year program that adds a large, durable revenue stream to its space systems segment but carries execution risk on a complex polar satellite mission. A key risk is the fixed-price structure on Northrop Grumman's contract, which could compress margins if cost overruns occur, while the two Caltech awards ($515M combined) offer no direct equity upside due to their cost-only or cost-plus-fee structures. The aggregate data reveals a stable, long-duration NASA investment cycle in polar weather satellites and early-stage space R&D, with no near-term re-compete pressure on the largest awards.

4 total filings
· daily

All HHS Contracts — May 20, 2026

Over a single-day period (May 20, 2026), HHS awarded $272.9M in obligations across four contracts, with 2 of 4 defense-related (BARDA) totaling $134.8M, signaling sustained biodefense and health security prioritization. The dominant theme is HHS/BARDA investment in antimicrobial resistance (AMR) and medical countermeasures, led by a $72.1M Venatorx Pharmaceuticals award with a $318.6M ceiling through 2032. The highest-conviction signal is Venatorx's cost-plus-fixed-fee structure and long performance period, providing low-risk, durable revenue in a high-priority national security area. Key risk: SELUX Diagnostics' contract ends May 2025, limiting future upside and creating a potential revenue cliff for that small business.

4 total filings
· daily

Mega Contracts Monitor ($100M+) — May 20, 2026

This digest covers $1.366 billion in civilian-only mega contracts (0/4 defense-related) awarded on a single day, May 20, 2026, with an average signal strength of 6.0/10. NASA dominates the period, accounting for $1.215 billion (89%) of total obligations across three awards to Northrop Grumman, Caltech/JPL, and RTX Corp (Raytheon). The highest-conviction signal is Northrop Grumman's $569.5M firm-fixed-price delivery order for the JPSS-2 spacecraft, a 13-year program with 8/10 bullish strength. Key risk: the fixed-price structure on a complex space vehicle introduces execution risk, while the civilian-only mix means no direct defense budget tailwind from NDAA priorities. The Department of Interior's $151.7M award to Centene's Magellan Federal for personal financial counselors is a neutral, non-core support contract with limited margin upside due to T&M pricing.

4 total filings
· daily

High-Value Federal Grants ($5M+) — May 20, 2026

This digest of 11 high-value federal grants, totaling $1.87 billion, reveals a pronounced civilian agency tilt, with only 2 of 11 contracts defense-related. NASA dominates the award landscape, accounting for over $1.28 billion across four contracts, including a $569.5 million firm-fixed-price delivery order to Northrop Grumman for the JPSS-2 spacecraft—the highest-conviction bullish signal. The strongest cross-contract pattern is NASA's sustained investment in space R&D and satellite programs, which benefits primes like Northrop Grumman and RTX Corp. However, the neutral average signal strength (5.2/10) and the absence of any bearish signals mask execution risk on fixed-price contracts and budget uncertainty under a potential Continuing Resolution. Key watch items include Northrop Grumman's JPSS-2 delivery milestones and the exercise of options on RTX's $200 million Landis flight instrument contract.

11 total filings